Literature DB >> 24682857

High-level production of Fc-fused kringle domain in Pichia pastoris.

Gu Min Jeong1, Yong Jae Lee, Yong Sung Kim, Ki Jun Jeong.   

Abstract

Recently, as a new non-immunoglobulin-based protein scaffold, a human kringle domain was successfully engineered toward biologically functional agonists and antagonists. In this study, the fed-batch cultivation conditions were optimized for enhanced production of an Fc-fused kringle domain (KD548-Fc) in Pichia pastoris. Fed-batch cultivations were performed in 5-l laboratory-scale bioreactors, and in order to find the optimal conditions for high-level production of KD548-Fc, several parameters including the initial carbon source (glycerol) concentration, temperature, and pH were investigated. When cells were cultivated at pH 4.0 and 25 °C with 9.5 % glycerol in the initial medium, the highest production yield (635 mg/l) was achieved with high productivity (7.2 mg/l/h). Furthermore, functional KD548-Fc was successfully purified from the culture broth using a simple purification procedure with high purity and recovery yield.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24682857     DOI: 10.1007/s10295-014-1435-2

Source DB:  PubMed          Journal:  J Ind Microbiol Biotechnol        ISSN: 1367-5435            Impact factor:   3.346


  24 in total

Review 1.  Engineered protein scaffolds for molecular recognition.

Authors:  A Skerra
Journal:  J Mol Recognit       Date:  2000 Jul-Aug       Impact factor: 2.137

Review 2.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 3.  Recombinant antibodies: engineering and production in yeast and bacterial hosts.

Authors:  Ki Jun Jeong; Seung Hoon Jang; Natarajan Velmurugan
Journal:  Biotechnol J       Date:  2011-01       Impact factor: 4.677

Review 4.  Engineered protein scaffolds as next-generation antibody therapeutics.

Authors:  Michaela Gebauer; Arne Skerra
Journal:  Curr Opin Chem Biol       Date:  2009-06-06       Impact factor: 8.822

5.  Strategies for production of active eukaryotic proteins in bacterial expression system.

Authors:  Orawan Khow; Sunutcha Suntrarachun
Journal:  Asian Pac J Trop Biomed       Date:  2012-02

6.  Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo.

Authors:  Chang-Han Lee; Kyung-Jin Park; Eun-Sil Sung; Aeyung Kim; Ji-Da Choi; Jeong-Sun Kim; Soo-Hyun Kim; Myung-Hee Kwon; Yong-Sung Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-11       Impact factor: 11.205

Review 7.  Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production.

Authors:  Rachel Daly; Milton T W Hearn
Journal:  J Mol Recognit       Date:  2005 Mar-Apr       Impact factor: 2.137

Review 8.  Heterologous protein production using the Pichia pastoris expression system.

Authors:  Sue Macauley-Patrick; Mariana L Fazenda; Brian McNeil; Linda M Harvey
Journal:  Yeast       Date:  2005-03       Impact factor: 3.239

9.  Low-temperature increases the yield of biologically active herring antifreeze protein in Pichia pastoris.

Authors:  Z Li; F Xiong; Q Lin; M d'Anjou; A J Daugulis; D S Yang; C L Hew
Journal:  Protein Expr Purif       Date:  2001-04       Impact factor: 1.650

10.  Production of monoclonal antibodies by glycoengineered Pichia pastoris.

Authors:  Thomas I Potgieter; Michael Cukan; James E Drummond; Nga Rewa Houston-Cummings; Youwei Jiang; Fang Li; Heather Lynaugh; Muralidhar Mallem; Troy W McKelvey; Teresa Mitchell; Adam Nylen; Alissa Rittenhour; Terrance A Stadheim; Dongxing Zha; Marc d'Anjou
Journal:  J Biotechnol       Date:  2008-12-27       Impact factor: 3.307

View more
  2 in total

1.  Development of a fed-batch process for a recombinant Pichia pastoris Δoch1 strain expressing a plant peroxidase.

Authors:  Christoph Gmeiner; Amirhossein Saadati; Daniel Maresch; Stanimira Krasteva; Manuela Frank; Friedrich Altmann; Christoph Herwig; Oliver Spadiut
Journal:  Microb Cell Fact       Date:  2015-01-08       Impact factor: 5.328

Review 2.  The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials.

Authors:  Martin Snajdauf; Klara Havlova; Jiri Vachtenheim; Andrej Ozaniak; Robert Lischke; Jirina Bartunkova; Daniel Smrz; Zuzana Strizova
Journal:  Front Mol Biosci       Date:  2021-03-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.